30 results about "Cerebral hypoxia" patented technology

The present disclosure relates to the use of 2-iminobiotin for treating brain cell injury, in particular in adults. The treatment may be used for the treatment of cerebral hypoxia-ischemia and / or reperfusion injury, including one or more symptoms thereof. Provided are methods of treatment comprising administering a therapeutically effective dose of 2-iminobiotin to an individual in need thereof.

The present invention is directed to a combination of therapeutic compounds and treatment methods and kits using the combination. In particular, one of the combination affects the NCCa-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system. Exemplary SUR1 and / or TRPM4 antagonists that inhibit the NCCa-ATP channel may be employed in the combination. The combination therapy also employs one or more of a non-selective cation channel blocker and / or an antagonist of VEFG, NOS, MMP, or thrombin. Exemplary indications for the combination therapy includes the prevention, diminution, and / or treatment of injured or diseased neural tissue, including astrocytes, neurons and capillary endothelial cells, that is due to ischemia, tissue trauma, brain swelling and increased tissue pressure, or other forms of brain or spinal cord disease or injury, for example. In other embodiments, there are methods and compositions directed to antagonists of TRPM4, including at least for therapeutic treatment of traumatic brain injury, cerebral ischemia, central nervous system (CNS) damage, peripheral nervous system (PNS) damage, cerebral hypoxia, or edema, for example.

A method of reducing the occurrence of brain cell damage or death caused by transient cerebral hypoxia, ischemia, brain inflammation or a traumatic brain injury (TBI) event. The method typically comprises identifying a subject with transient cerebral hypoxia, ischemia, brain inflammation or a TBI, and within 24 hours of onset of the condition, administering to the subject a continuous intravenous infusion dose of methamphetamine in an amount sufficient to reduce the occurrence of brain cell damage or death caused by the condition. Preferably, the dose is increased in response to a delay in administration. The invention also relates to a method for modulating cytokine expression within the brain to treat such conditions.

The invention relates to the technical field of Chinese herbal medicines, and in particular relates to a traditional Chinese medicine preparation of an external oxygenation pill, and preparation and using methods thereof. The traditional Chinese medicine preparation comprises the following effective raw materials in parts by weight: 400-600 parts of pine pollen, 100-200 parts of acacia catechu, 50-100 parts of asarum sieboldii, 150-300 parts of siberian cocklour fruit, 100-200 parts of flos magnoliae liliflorae, 100-200 parts of Chinese honeylocust fruit, 80-150 parts of rhizoma nelumbinis, 100-200 parts of angelica dahurica and 100-300 parts of green Chinese onion. A soybean-shaped pill is prepared from the raw materials and is placed in a nostril; the most remarkable effect is achieved in cooperation with a fumigating therapy; after the pill is taken out, the nostril approaches the lower part of a bowl containing boiled fumigating drugs including 4-7 parts of flos magnoliae liliflorae, 15-25 parts of siberian cocklour fruit, 10-18 parts of angelica dahurica, 15-30 parts of lily and 5-15 parts of green Chinese onion, and is fumigated. The traditional Chinese medicine preparation has the advantages that the components are simple; a formula is reasonable; a remarkable treatment effect is achieved; cerebral hypoxia and headache caused by altitude stress and altitude anoxia, nasal obstruction and headache caused by rhinitis, dyspnea and pneumonia caused by cold and the like are mainly treated.

Salvinorin A for use in treating neurological injuries associated with cardiac arrest, treating stroke, or treating a cerebral artery occlusion, cerebral hypoxia / ischemia or cerebral vasospasm in a subject.

A method of reducing the occurrence of brain cell damage or death caused by transient cerebral hypoxia / ischemia condition or a traumatic brain injury (TBI) event. The method typically comprises identifying a subject with a transient cerebral hypoxic and / or ischemic condition, or a TBI, and within 24 hours of onset of the condition, administering to the subject a continuous intravenous infusion dose of methamphetamine in an amount sufficient to reduce the occurrence of brain cell damage or death caused by the condition. Preferably, in addition to the continuous intravenous infusion dose, a bolus dose of methamphetamine is administered to the subject as soon as possible after onset of the condition or occurrence of the TBI event.

The invention relates to a method for extracting a common macrocarpium fruit total glycoside and application of the common macrocarpium fruit total glycoside serving as active ingredients to the preparation of hypoxia tolerant medicines. The method comprises the following steps of: boiling, performing enzymolysis for extracting and purifying. The pharmacodynamic test proves that the common macrocarpium fruit total glycoside extracted by the method can improve the cardio-cerebral hypoxia capacity of mice, enhance physical strength, improve antifatigue capacity of organisms, and promote the establishment of hypoxia tolerant acclimatization.

The invention discloses a medicine for treating cardiovascular and cerebrovascular diseases. It is a traditional Chinese medicine injection prepared by extracting and purifying Radix Astragali and Panax notoginseng as raw materials, and adding appropriate amount of medicinal auxiliary materials, including injection, large infusion and freeze-dried powder injection. The invention also discloses a preparation method of the medicine. The medicine of the invention has good stability and long effective period, and can be used for intramuscular injection, intravenous injection or intravenous drip. Pharmacodynamic tests show that the medicine of the present invention has protective effects on cerebral ischemia and myocardial injury in SD rats caused by ischemia-reperfusion. It can significantly improve the ability of mice to withstand cerebral hypoxia, improve neurological symptoms and cerebral edema in rats with cerebral ischemia, and reduce pathological changes; it can obviously inhibit the overflow of LDH and CK during myocardial injury in rats caused by ischemia-reperfusion, and reduce serum LDH, CK activity, narrowing the range of myocardial infarction, for the treatment of cardiovascular and cerebrovascular diseases, rapid onset, definite curative effect, no toxic side effects.